Article

Bausch & Lomb plans to acquire eyeonics inc.

Bausch & Lomb has entered into a final agreement to obtain eyeonics inc.

Rochester, NY and Aliso Viejo, CA-Bausch & Lomb has entered into a final agreement to obtain eyeonics inc. Financial terms were not disclosed but the transaction is expected to close during the first quarter of 2008 subject to standard regulatory approval.

On completion of this agreement, eyeonics' operations will become part of Bausch & Lomb's surgical business, which offers a complete line of standard IOLs, phacoemulsification equipment, and vitreoretinal and refractive products.

The U.S. surgical business will be led by J. Andy Corley, eyeonics' co-founder, chairman, and chief executive officer (CEO).

The transaction includes eyeonics' IOL (crystalens), the first and only FDA-approved accommodating lens

"This acquisition immediately places Bausch & Lomb into the rapidly expanding premium IOL market. The [lens] technology complements our existing cataract surgical business, including our vision enhancement system [Stellaris] and our portfolio of monofocal IOLs," said Ronald L. Zarrella, chairman and CEO, Bausch & Lomb. "The acquisition also adds leadership depth, as Andy and his team bring a strong track record of product innovation and growth to the company. We look forward to their contributions as part of the Bausch & Lomb family."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.